Skip to main content

Table 2 Results according to initial visual acuity

From: Funduscopic results after 4-year follow-up treatment with ranibizumab for age-related macular degeneration in a region of Spain

 

G1: Initial VA <0.3 logMAR

G2: Initial VA [0.3-1]

G3: Initial VA >1 logMAR

Kurskal-Wallis p-value

Pairwise comparisons

G1 vs G2

G1 vs G3

G2 vs G3

VA 3 months

0.25 ± 0.31

0.62 ± 0.37

1.23 ± 0.5

<0.0001

<0.0001

<0.0001

<0.0001

VA 1 year

0.26 ± 0.31

0.75 ± 0.45

1.28 ± 0.57

<0.0001

<0.0001

<0.0001

<0.0001

VA 2 year

0.44 ± 0.45

0.98 ± 0.6

1.36 ± 0.57

<0.0001

<0.0001

<0.0001

<0.0001

VA 3 year

0.59 ± 0.52

1.02 ± 0.61

1.38 ± 0.69

<0.0001

0.0009

<0.0001

0.0093

VA 4 year

0.58 ± 0.46

1.08 ± 0.59

1.53 ± 0.48

<0.0001

0.0054

0.0001

0.0036

N Injections 3 months

2.64 ± 0.49

2.65 ± 0.49

2.58 ± 0.5

0.604

1

1

0.9569

N Injections 1 year

4.31 ± 1.95

4.09 ± 1.46

3.39 ± 1.18

0.0006

1

0.0356

0.0004

N Injections 2 year

1.41 ± 1.67

1.23 ± 1.61

0.61 ± 1.16

0.0025

1

0.0352

0.0023

N Injections 3 year

2.22 ± 2.58

1.48 ± 2.45

1.38 ± 2.05

0.1571

0.194

0.2912

1

N Injections 4 year

2.67 ± 3.5

1.8 ± 3.26

1.65 ± 2.18

0.4688

0.7252

1

1

N Visits 3 months

3 ± 0.69

2.71 ± 0.77

2.54 ± 0.75

0.0325

0.1425

0.0237

0.5999

N Visits 1 year

7.64 ± 2.19

7.41 ± 2.09

6.94 ± 2.36

0.3902

1

0.7785

0.66

N Visits 2 year

4.91 ± 2.85

5.36 ± 2.55

5.22 ± 2.93

0.4769

0.7832

1

1

N Visits 3 year

4 ± 2.6

4.13 ± 2.35

3.41 ± 2.34

0.1449

1

1

0.1457

N Visits 4 year

3.77 ± 2.77

3.81 ± 2.16

3 ± 2.25

0.2883

1

1

0.3264

Age (years)

75.28 ± 8

78.31 ± 7.36

80.1 ± 7.21

0.0092

0.0939

0.0109

0.2121

  1. VA Visual Acuity, N number, G1 group 1, G2 group 2, G3 group 3, vs versus.
  2. Statistical significant p values are in bold.
Back to article page

BMC Ophthalmology

ISSN: 1471-2415

Contact us